Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.
Pamidronate is used frequently to treat malignancy-associated hypercalcemia and osteolytic lesions. This widely used bisphosphonate has been noted to cause nephrotoxicity in patients with multiple myeloma and metastatic breast cancer. We encountered a patient with Langerhans's histiocytosis who developed nephrotic syndrome and renal failure after pamidronate therapy. We describe the clinical and renal biopsy findings in this patient.
Lockridge
Les
L
Department of Medicine, Section of Oncology and Section of Nephrology, Yale University, New Haven, CT 06529-8029, USA.
Papac
Rose J
RJ
Perazella
Mark A
MA
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D008854:Microscopy, Electron; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000473:pathology; D000077268:Pamidronate; D051437:Renal Insufficiency / Q000139:chemically induced / Q000473:pathology
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate